We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals
ATNM

28 hedge funds and large institutions have $6.39M invested in Actinium Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 1

0.19% less ownership

Funds ownership: 0.59% → 0.4% (-0.19%)

10% less funds holding

Funds holding: 31 → 28 (-3)

22% less capital invested

Capital invested by funds: $8.16M → $6.39M (-$1.77M)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $18K

Holders
28
Holders Change
-3
Holders Change %
-9.68%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
11
Reduced
1
Closed
6
Calls
–
Puts
$18K
Net Calls
-$18K
Net Calls Change
-$57K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$230K
2
UBS Group
UBS Group
Switzerland
+$109K
3
DADC
D.A. Davidson & Co
Montana
+$73.1K
4
AC
Armistice Capital
New York
+$55K
5
CS
Credit Suisse
Switzerland
+$40.4K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1.4M
2
SCM
Sio Capital Management
New York
-$915K
3
AFM
Anson Funds Management
Texas
-$589K
4
DCM
DAFNA Capital Management
California
-$192K
5
Citadel Advisors
Citadel Advisors
Florida
-$34K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$2.96M +$55K +2,733 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.65M +$230K +11,431 +16%
CS
3
Credit Suisse
Switzerland
$538K +$40.4K +2,007 +8%
BlackRock
4
BlackRock
New York
$437K +$22.7K +1,131 +5%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$126K – – –
BCM
6
Bridgeway Capital Management
Texas
$114K – – –
UBS Group
7
UBS Group
Switzerland
$108K +$109K +5,403 New
DADC
8
D.A. Davidson & Co
Montana
$104K +$73.1K +3,633 +227%
Northern Trust
9
Northern Trust
Illinois
$71K – – –
VF
10
Virtu Financial
New York
$65K +$37.6K +1,870 +134%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$35K +$3.28K +163 +10%
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$27K – – –
ARTA
13
A.R.T. Advisors
New York
$26K +$6.32K +314 +31%
RJFSA
14
Raymond James Financial Services Advisors
Florida
$17K +$4.69K +233 +38%
Morgan Stanley
15
Morgan Stanley
New York
$16K -$684 -34 -4%
DY
16
Dowling & Yahnke
California
$15K – – –
TSS
17
Two Sigma Securities
New York
$14K +$2.01K +100 +17%
SFG
18
SNS Financial Group
Minnesota
$13K +$1.35K +67 +11%
HFM
19
Hartford Financial Management
Connecticut
$11K – – –
Barclays
20
Barclays
United Kingdom
$10K – – –
State Street
21
State Street
Massachusetts
$8K – – –
SXL
22
Summit X LLC
Missouri
$8K – – –
Macquarie Group
23
Macquarie Group
Australia
$8K +$8.51K +423 New
AG
24
Advisor Group
Arizona
$3K – – –
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$2K – – –
1
2

ATNM Hedge Fund Activity: Q4 2017 in Review

28 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2017, worth a combined $6.39M — down 22% from $8.16M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ATNM and 3 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 11 added.

The largest buyer was Vanguard Group, adding an estimated $230K. The largest seller was Sabby Management, exiting entirely with an estimated $1.4M sold.

  • 28 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2017, down from 31 in Q3 2017.
  • Funds reported $6.39M of Actinium Pharmaceuticals stock for Q4 2017, down 22% quarter-over-quarter.
  • 3 funds opened new Actinium Pharmaceuticals positions in Q4 2017 and 6 closed out, a net change of -3 holders.
  • The largest Actinium Pharmaceuticals buyer in Q4 2017 was Vanguard Group, an estimated $230K added.
  • The largest Actinium Pharmaceuticals seller in Q4 2017 was Sabby Management, an estimated $1.4M sold.

Based on aggregated 13F filings for Q4 2017.